Moneycontrol
HomeNewsBusinessStartupCovid-19 | VCs on the prowl for a good startup hunt in virus storm 

Covid-19 | VCs on the prowl for a good startup hunt in virus storm 

Deals worth more than $120 million struck in April alone, as investors look to make the most of soft valuations and a bigger shift towards tech in the post-COVID-19 world.    

May 12, 2020 / 09:53 IST
Story continues below Advertisement
Representative image

Much against the conventional wisdom that investors claw back during rainy days, several venture capital (VC) funds are out shopping, striking deals and writing cheques even as the coronavirus outbreak continues to hurt the economy, pushing businesses to the brink. 

Surplus capital, soft valuation of startups, a shift towards tech in a post-coronavirus world and family offices looking to diversify asset base in times of economic uncertainty are some of the reasons for the ongoing funding activity.

Story continues below Advertisement

Take the example of online vernacular competitive test preparation startup Pariksha. The company signed term sheets, a non-binding document that spells out the broader contours of the arrangement, with investors for an extension of its pre-Series A round at the beginning of March.

On March 24 when Prime Minister Narendra Modi announced a lockdown on national television, the founders got jittery. Some of the promised money was in the bank but the rest was yet to come. 

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show